What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Small Interfering RNA: Mechanism, Function, and Applications

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Small Interfering RNA

Small interfering RNA (siRNA) is a class of double-stranded RNA molecules, typically 20–24 nucleotides in length, that function within the RNA interference (RNAi) pathway to silence gene expression post-transcriptionally. Each siRNA duplex consists of a guide (antisense) strand and a passenger (sense) strand, with characteristic two-nucleotide 3′ overhangs on both ends. These short duplexes are the effector molecules of RNAi, a conserved eukaryotic mechanism that recognizes complementary messenger RNA (mRNA) transcripts and directs their destruction or translational repression.

The discovery of RNAi emerged from unexpected observations in plants and invertebrates. In 1990, researchers attempting to deepen petunia flower color by introducing additional chalcone synthase genes instead observed white or variegated flowers, a phenomenon termed co-suppression. The mechanistic breakthrough came in 1998 when Andrew Fire and Craig Mello injected double-stranded RNA (dsRNA) into Caenorhabditis elegans and demonstrated that dsRNA—not the individual sense or antisense strands—was the potent trigger of gene silencing. They showed that dsRNA produced sequence-specific mRNA degradation far more efficiently than either single strand alone, a finding that earned them the 2006 Nobel Prize in Physiology or Medicine. Subsequent work in Drosophila melanogaster embryo lysates by Thomas Tuschl and colleagues in 1999 identified the processed siRNA products of dsRNA, establishing the molecular framework of the RNAi pathway.

Discovery of RNAi

The RNAi pathway can be divided into two phases: initiation and effector. During initiation, long dsRNA molecules—whether introduced experimentally, produced from viral replication intermediates, or transcribed from endogenous loci—are processed by the RNase III enzyme Dicer into siRNA duplexes. During the effector phase, one strand of the siRNA is loaded into the RNA-induced silencing complex (RISC), where it guides the sequence-specific recognition of complementary mRNA. This recognition typically results in endonucleolytic cleavage of the target transcript, although alternative silencing outcomes are possible depending on the degree of complementarity and the cellular context.

siRNA vs. miRNA

Small interfering RNA and microRNA (miRNA) share the Dicer/RISC machinery but differ in their origins, structures, and modes of target regulation. siRNA is derived from perfectly complementary long dsRNA, either exogenous (viral, experimental) or endogenous (from transposons or convergent transcription). miRNA, by contrast, is transcribed from endogenous genes as primary miRNA (pri-miRNA) hairpins, processed in the nucleus by the Drosha–DGCR8 complex into precursor miRNA (pre-miRNA), and then exported to the cytoplasm for Dicer processing. Functionally, siRNA typically directs perfect base-pairing with its target mRNA, leading to site-specific cleavage. miRNA usually binds with imperfect complementarity to the 3′ untranslated region (UTR) of target mRNAs, promoting translational repression and mRNA destabilization rather than direct cleavage. For a more detailed comparison of these small RNA classes, see Small RNA vs Microrna.

Biogenesis of Small Interfering RNA

The production of functional siRNA from long dsRNA precursors is a two-step process involving Dicer processing and RISC loading. Both steps are tightly regulated and require specific protein cofactors that ensure the correct strand is selected and the correct target is silenced.

Dicer Processing

Dicer is a large (~200 kDa) multidomain RNase III-family enzyme that cleaves long dsRNA into siRNA duplexes. The enzyme contains an N-terminal DExD/H-box helicase domain, a DUF283 domain, a PAZ (Piwi-Argonaute-Zwille) domain, two RNase III domains, and a C-terminal dsRNA-binding domain. The PAZ domain binds the 3′ ends of the dsRNA substrate, anchoring the enzyme at a defined distance from the terminus. The two RNase III domains form an intramolecular dimer that positions two catalytic sites across the dsRNA, cleaving both strands at staggered positions. This produces a duplex with 5′ phosphate groups and 2-nucleotide 3′ overhangs, the canonical siRNA signature.

Dicer processing occurs in the cytoplasm for most exogenous dsRNA. In mammals, a single Dicer isoform processes both siRNA and miRNA precursors, whereas Drosophila expresses two Dicer paralogs: Dicer-1 for pre-miRNA and Dicer-2 for long dsRNA. The cleavage reaction requires ATP for processive dicing in some organisms, although the basic endonucleolytic step can proceed without ATP. The resulting siRNA duplex is typically 21–23 nucleotides long, with the exact length determined by the distance between the PAZ domain and the RNase III catalytic centers.

The efficiency of Dicer processing depends on the structural features of the dsRNA substrate. Perfectly base-paired dsRNA of at least 30 base pairs is processed efficiently, while shorter duplexes or those with internal bulges are processed poorly. This length requirement provides a natural discrimination against short hairpin structures that might otherwise trigger inappropriate silencing.

RISC Loading and Strand Selection

Following Dicer processing, the siRNA duplex must be loaded into the RNA-induced silencing complex. The core component of RISC is an Argonaute (Ago) protein, a ~100 kDa protein containing PAZ, MID, and PIWI domains. The PIWI domain adopts an RNase H-like fold and provides the endonucleolytic activity for target cleavage in Ago2, the only human Argonaute with slicer activity.

Loading is mediated by the RISC-loading complex, which in humans contains Dicer, the dsRNA-binding protein TRBP (TAR RNA-binding protein), and Ago2. The siRNA duplex is transferred from Dicer to Ago2 in an ATP-dependent process. The PAZ domain of Ago2 binds the 3′ end of the guide strand, while the MID domain anchors the 5′ phosphate. The duplex is unwound, and the strand with the less thermodynamically stable 5′ end is preferentially retained as the guide strand. This asymmetry rule arises because the strand whose 5′ end is more weakly base-paired is more readily unwound by the helicase activity associated with the loading complex. The passenger strand is subsequently cleaved by Ago2 (if it is a perfect duplex) or otherwise discarded and degraded.

The selection of the guide strand is critical for specificity. If the wrong strand is loaded, the RISC will silence unintended targets. The thermodynamic asymmetry rule—that the strand with the lower 5′ stability becomes the guide—is exploited in siRNA design to ensure that the desired strand is preferentially loaded. The 5′ nucleotide identity also influences strand selection: Ago2 shows a preference for loading guides with 5′ uridine or adenosine.

Mechanism of Gene Silencing by siRNA

The silencing of gene expression by siRNA proceeds through a series of ordered steps once the guide strand is loaded into RISC. The activated RISC, often termed holo-RISC, scans cytoplasmic mRNAs for complementarity to the guide strand. This scanning is not an active process but relies on the random collision of RISC with mRNA molecules, with the guide strand base-pairing to accessible, single-stranded regions of the transcript.

mRNA Cleavage

When the guide strand finds a target mRNA with perfect or near-perfect complementarity, the PIWI domain of Ago2 catalyzes endonucleolytic cleavage of the mRNA. The cleavage occurs between nucleotides 10 and 11 of the guide strand, counting from the 5′ end. This position corresponds to the catalytic center of the PIWI domain, which coordinates two magnesium ions to activate a water molecule for nucleophilic attack on the phosphodiester backbone.

The cleavage reaction produces two mRNA fragments: a 5′ fragment with a 3′ hydroxyl group and a 3′ fragment with a 5′ phosphate. These fragments are rapidly degraded by cellular exonucleases, including the exosome and XRN1, preventing any possibility of translation. The RISC complex is not consumed in the reaction and can proceed to cleave additional mRNA molecules, making siRNA-mediated silencing catalytic. A single RISC can cleave multiple transcripts, providing potent and sustained gene silencing.

The efficiency of cleavage depends on the accessibility of the target site. Regions of mRNA that are highly structured or bound by RNA Binding Proteins are poor targets, whereas unstructured regions, particularly in the coding sequence or 3′ UTR, are more accessible. This is why siRNA design algorithms incorporate secondary structure prediction to identify accessible target sites.

Translational Repression and Other Silencing Mechanisms

Although mRNA cleavage is the primary mechanism for perfectly complementary siRNA targets, siRNAs can also silence genes through translational repression and mRNA destabilization when complementarity is imperfect. In mammals, Ago2-bound siRNAs with central mismatches can recruit GW182 family proteins, which in turn recruit the CCR4-NOT deadenylase complex. Deadenylation triggers decapping and 5′-to-3′ mRNA degradation, effectively silencing the gene without direct endonucleolytic cleavage.

Additionally, siRNAs can promote transcriptional gene silencing (TGS) in some contexts. In the nucleus, Ago proteins associated with siRNAs can recruit histone methyltransferases and DNA methyltransferases to homologous genomic loci, leading to heterochromatin formation and transcriptional repression. This mechanism is well-characterized in fission yeast (Schizosaccharomyces pombe) and has been observed in mammalian cells, particularly at repetitive elements and transposon-derived sequences. The nuclear RNAi pathway also involves the Small Nuclear RNA machinery for some processing steps, though the details differ between organisms.

Biological Functions of Small Interfering RNA

Endogenous siRNAs serve diverse biological roles across eukaryotes, functioning primarily as a defense against foreign nucleic acids and as regulators of genome stability. These functions are particularly prominent in plants, invertebrates, and fungi, while mammals have evolved a more restricted endogenous siRNA system.

Antiviral Immunity

In plants, nematodes, and insects, siRNA-mediated RNAi is a major antiviral defense mechanism. When a virus infects a cell, its replication intermediates—often long dsRNA—are recognized by Dicer and processed into virus-derived siRNAs (vsiRNAs). These vsiRNAs are loaded into RISC and direct the cleavage of viral mRNA, limiting viral replication and spread. In Drosophila, the antiviral response is mediated by Dicer-2 and Ago2, and flies mutant for these genes show enhanced susceptibility to viral infection.

Plants lack an adaptive immune system and rely heavily on RNAi for antiviral defense. The systemic spread of silencing signals through plasmodesmata allows plants to mount a coordinated antiviral response across tissues. Many plant viruses have evolved suppressors of RNAi, such as the P19 protein of tombusviruses, which binds siRNA duplexes and prevents RISC loading—evidence of the evolutionary arms race between viruses and host RNAi.

In mammals, the antiviral role of RNAi is less prominent because the interferon response provides a more immediate defense. However, the interferon response itself is triggered by dsRNA, and Dicer processing of viral dsRNA can contribute to the production of immunostimulatory small RNAs. Some viruses, including certain RNA viruses, are susceptible to siRNA-mediated silencing in mammalian cells, and this has been exploited experimentally.

Genome Stability

Endogenous siRNAs also protect genome integrity by silencing transposable elements. Transposons are mobile genetic elements whose uncontrolled activity can cause insertional mutations and genomic instability. In many organisms, transposon-derived transcripts form dsRNA either through self-complementary hairpins or through convergent transcription from opposite strands. These dsRNAs are processed into siRNAs that guide the deposition of repressive chromatin marks at transposon loci.

In fission yeast, the RNA-induced transcriptional silencing (RITS) complex, containing Ago1, Chp1, and Tas3, directs histone H3 lysine 9 methylation at centromeric repeats, establishing heterochromatin. In Drosophila, the Piwi-interacting RNA (piRNA) pathway—a related but distinct small RNA system—plays the dominant role in transposon silencing in the germline. In mammals, endogenous siRNAs are rare, but the piRNA pathway is essential for transposon silencing in the male germline.

Endogenous siRNAs can also regulate protein-coding genes. In C. elegans, endogenous siRNAs derived from transposons and other repetitive elements can target cellular mRNAs in trans, contributing to gene regulation. In plants, endogenous siRNAs derived from natural antisense transcripts (nat-siRNAs) regulate stress-responsive genes. These examples illustrate that the biological functions of siRNA extend beyond simple antiviral defense to include developmental regulation and stress responses.

Methods to Study Small Interfering RNA

The study of siRNA function relies on the ability to introduce siRNAs into cells and measure the resulting gene silencing. Synthetic siRNA transfection is the most common approach, but the design, delivery, and interpretation of results require careful attention to experimental controls.

siRNA Design Tools

Effective siRNA design is governed by several empirical rules. The guide strand should have a 5′ end with lower thermodynamic stability than the passenger strand to favor guide loading. The sequence should be 19–21 nucleotides long with a GC content between 30% and 50%. The target site should be in the coding sequence or 3′ UTR, avoiding regions of high secondary structure. Off-target potential is minimized by ensuring that the seed region (nucleotides 2–8 of the guide) has limited complementarity to unintended mRNAs.

Several web-based tools implement these rules, including the Whitehead Institute's siRNA Selection Program, Dharmacon's siDESIGN Center, and the Broad Institute's GPP portal. These tools score candidate siRNAs based on thermodynamic properties, sequence features, and predicted off-target matches. For a typical gene, 3–5 independent siRNAs are designed and tested to confirm consistent silencing phenotypes.

Synthetic siRNAs are typically delivered to cells by lipid-based transfection reagents. A standard protocol for adherent mammalian cells uses 10–50 nM siRNA complexed with a cationic lipid such as Lipofectamine RNAiMAX in serum-free medium. The complexes are added to cells at 30–50% confluency, and silencing is assessed 24–72 hours post-transfection by quantitative RT-PCR (qRT-PCR) for mRNA levels and Western blot for protein levels. For hard-to-transfect cells such as primary neurons or immune cells, electroporation or viral delivery of short hairpin RNA (shRNA) may be necessary.

Off-Target Effects and Controls

Off-target effects are a major concern in siRNA experiments. These arise when the guide strand has partial complementarity to unintended mRNAs, particularly through seed-region matches that mimic miRNA-like regulation. Additionally, the passenger strand can be loaded into RISC and silence unintended targets. The introduction of exogenous siRNA can also trigger the innate immune response through activation of Toll-like receptors (TLR3, TLR7, TLR8) and the RIG-I-like receptors, leading to non-specific gene expression changes.

To control for off-target effects, several strategies are employed. First, multiple independent siRNAs targeting the same gene should produce the same phenotype; if they do not, the phenotype may be due to off-target silencing. Second, a non-targeting siRNA (a scrambled sequence with no predicted mRNA targets) should be used as a negative control. Third, rescue experiments—expressing a siRNA-resistant version of the target gene—confirm that the phenotype is due to silencing of the intended target. Fourth, genome-wide expression profiling can identify off-target transcripts and confirm that the intended target is the most strongly downregulated gene.

The use of chemical modifications can reduce off-target effects. 2′-O-methyl modifications at position 2 of the guide strand reduce seed-region binding to unintended targets without affecting on-target silencing. Similarly, the incorporation of unlocked nucleobase analogs or the use of DNA in the passenger strand can reduce passenger-strand loading.

Therapeutic and Biotechnological Applications

The sequence-specific gene silencing capability of siRNA has made it a powerful tool for both basic research and clinical applications. The ability to knock down any gene of known sequence has revolutionized functional genomics, while the development of chemically stabilized siRNAs has enabled their use as therapeutic agents.

siRNA-Based Drugs

The first siRNA therapeutic, patisiran (Onpattro), was approved by the U.S. Food and Drug Administration in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis. Patisiran is a lipid nanoparticle-formulated siRNA that targets the transthyretin (TTR) mRNA, reducing the production of the misfolded TTR protein that accumulates in tissues. The lipid nanoparticle formulation protects the siRNA from nuclease degradation and facilitates delivery to hepatocytes, which express the TTR gene.

Subsequent approvals have expanded the therapeutic landscape. Givosiran (Givlaari), approved in 2019, targets aminolevulinate synthase 1 (ALAS1) for the treatment of acute hepatic porphyria. Lumasiran (Oxlumo), approved in 2020, targets hydroxyacid oxidase 1 (HAO1) to reduce oxalate production in primary hyperoxaluria type 1. Inclisiran (Leqvio), approved in 2021, targets proprotein convertase subtilisin/kexin type 9 (PCSK9) to lower LDL cholesterol. These drugs use a different delivery platform—N-acetylgalactosamine (GalNAc) conjugation—which enables specific uptake by hepatocytes via the asialoglycoprotein receptor and allows subcutaneous administration.

The success of these drugs relies on chemical modifications that enhance stability and reduce immunogenicity. The 2′-O-methyl and 2′-fluoro modifications on the ribose sugar protect against nucleases, while phosphorothioate linkages in some positions increase resistance to exonuclease degradation. The GalNAc conjugation enables receptor-mediated endocytosis, and the enhanced stability allows sustained silencing for months after a single dose.

Agricultural Applications

Beyond human therapeutics, siRNA technology has applications in agriculture. RNAi-based crop protection exploits the fact that plants can take up dsRNA and process it into siRNAs that silence pest genes. Transgenic plants expressing dsRNA targeting essential pest genes can confer resistance to insects, nematodes, and fungi. For example, corn engineered to express dsRNA targeting the vacuolar ATPase of the western corn rootworm (Diabrotica virgifera virgifera) has been developed commercially.

Spray-induced gene silencing (SIGS) is an alternative approach that avoids genetic modification. In SIGS, dsRNA or siRNA is applied topically to plant surfaces, where it is taken up by the plant or by feeding pests. This approach has shown promise against fungal pathogens such as Fusarium graminearum and Botrytis cinerea. The environmental fate of applied siRNAs and the potential for off-target effects on non-target organisms remain active areas of investigation.

Common Pitfalls and Misconceptions

Several recurring errors plague siRNA experiments and interpretations. Understanding these pitfalls is essential for designing rigorous experiments and interpreting published data correctly.

siRNA vs. shRNA

Short hairpin RNA (shRNA) is often confused with siRNA, but they are distinct reagents. shRNA is a single-stranded RNA molecule that forms a hairpin structure with a stem of 19–29 base pairs and a loop of 4–10 nucleotides. It is typically expressed from a DNA vector (plasmid or viral) using RNA polymerase III promoters such as U6 or H1. The shRNA transcript is exported to the cytoplasm, where Dicer processes it into siRNA duplexes, which then enter the RISC pathway.

The choice between siRNA and shRNA depends on the experimental context. siRNA is transient, with silencing typically lasting 3–7 days, and is suitable for short-term knockdown experiments. shRNA provides stable, long-term silencing and is suitable for studying chronic phenotypes or for in vivo applications where sustained knockdown is required. However, shRNA requires cloning and viral packaging, which is more time-consuming. Additionally, shRNA expression can saturate the endogenous miRNA pathway, causing toxicity, particularly at high expression levels.

Experimental Pitfalls

A common experimental pitfall is the failure to validate siRNA specificity. Many published siRNA sequences have been shown to silence unintended targets, leading to incorrect conclusions about gene function. The minimum standard for a rigorous siRNA experiment includes: (1) at least two independent siRNAs targeting different regions of the same gene, (2) a non-targeting negative control, (3) confirmation of target knockdown at both mRNA and protein levels, and (4) a rescue experiment where possible.

Another pitfall is the misinterpretation of phenotypic data when silencing is incomplete. A 50% reduction in protein levels may be insufficient to produce a phenotype if the protein is in excess, or it may produce a phenotype that is not representative of complete loss of function. Conversely, a phenotype observed with partial knockdown may be due to a threshold effect that does not reflect the gene's normal function. Dose-response experiments with varying siRNA concentrations can help establish the relationship between knockdown efficiency and phenotype.

The immune stimulation by siRNAs is another frequently overlooked issue. Unmodified siRNAs can activate TLR3, TLR7, and TLR8 in immune cells, inducing type I interferons and inflammatory cytokines. This can produce phenotypes unrelated to target silencing. The use of chemically modified siRNAs (2′-O-methyl, 2′-fluoro) or the inclusion of a control siRNA with the same chemical modifications but no target reduces this problem. For a broader discussion of small RNA classes and their distinctions, see Small RNA Containing Particles.

Summary and Key Takeaways

Small interfering RNA is a central component of the RNAi pathway, providing sequence-specific gene silencing in eukaryotes. The pathway is initiated by Dicer processing of long dsRNA into 21–23-nucleotide duplexes, followed by RISC loading and guide-strand selection. The activated RISC recognizes complementary mRNA and cleaves it through the endonucleolytic activity of Ago2, although alternative silencing mechanisms exist for imperfectly matched targets. Biologically, siRNAs defend against viruses and transposons, and they regulate gene expression in diverse organisms. Experimentally, synthetic siRNAs are powerful tools for functional genomics, while chemically stabilized siRNAs have become approved therapeutics for several genetic and metabolic diseases.

Frequently Asked Questions

What is small interfering RNA?

Small interfering RNA (siRNA) is a double-stranded RNA molecule of 20–24 nucleotides that mediates sequence-specific gene silencing through the RNA interference pathway. It consists of a guide strand that is loaded into the RNA-induced silencing complex and a passenger strand that is degraded. siRNAs are produced from long double-stranded RNA by the enzyme Dicer.

What is the function of small interfering RNA?

The primary function of siRNA is to silence gene expression post-transcriptionally by guiding the cleavage of complementary mRNA transcripts. In natural contexts, siRNAs defend against viral infection, silence transposable elements to maintain genome stability, and regulate endogenous gene expression. Experimentally, siRNAs are used to knock down specific genes to study their function.

How does siRNA silence genes?

siRNA silences genes by loading the guide strand into the RNA-induced silencing complex (RISC). The guide strand base-pairs with complementary mRNA, and the Argonaute protein within RISC cleaves the mRNA between nucleotides 10 and 11 of the guide. The cleaved mRNA is rapidly degraded, preventing translation. With imperfect complementarity, siRNA can also repress translation and promote mRNA destabilization.

What is the difference between siRNA and miRNA?

siRNA is derived from long, perfectly complementary double-stranded RNA and typically directs cleavage of a single target mRNA with perfect complementarity. miRNA is transcribed from endogenous genes as hairpin precursors, processed by Drosha and Dicer, and usually binds with imperfect complementarity to multiple target mRNAs, repressing translation and promoting mRNA degradation. For more detail, see Small RNA vs Microrna.

How is siRNA produced in cells?

siRNA is produced from long double-stranded RNA by the RNase III enzyme Dicer. Dicer binds the dsRNA, cleaves it at staggered positions, and releases 21–23-nucleotide duplexes with 2-nucleotide 3′ overhangs. The duplex is then loaded into the RISC-loading complex, where one strand is selected as the guide and the other is degraded.

What are the applications of siRNA?

siRNA has applications in functional genomics, where it is used to knock down genes and study their phenotypes. Therapeutically, siRNA drugs such as patisiran, givosiran, lumasiran, and inclisiran are approved for treating genetic and metabolic diseases. In agriculture, RNAi-based approaches are used for crop protection against pests and pathogens.

What are off-target effects of siRNA?

Off-target effects are unintended gene silencing events caused by siRNA. They arise when the guide strand has partial complementarity to mRNAs other than the intended target, particularly through seed-region matches. The passenger strand can also cause off-target silencing if it is loaded into RISC. Chemical modifications and careful experimental design, including multiple independent siRNAs and appropriate controls, help minimize off-target effects.

Key Takeaways

siRNA is a 20–24-nucleotide double-stranded RNA that mediates sequence-specific gene silencing through the RNAi pathway.
Dicer processes long dsRNA into siRNA duplexes, and the guide strand is loaded into RISC, where Ago2 cleaves complementary mRNA.
The thermodynamic stability of the 5′ ends determines which strand is loaded as the guide.
Endogenous siRNAs function in antiviral defense, transposon silencing, and gene regulation across eukaryotes.
Synthetic siRNAs are powerful research tools, but off-target effects and immune stimulation require rigorous controls.
Chemically modified siRNAs have been developed into approved therapeutics for transthyretin amyloidosis, porphyria, primary hyperoxaluria, and hypercholesterolemia.
siRNA and shRNA are distinct reagents with different kinetics, delivery requirements, and experimental applications.